Medical Oncology

, Volume 15, Issue 1, pp 37–43 | Cite as

Inhibition of systemic TNF-alpha cytotoxicity in cancer patients by D-peptidoglycan

  • Vladimir I Slesarev
  • Rita Ellithorpe
  • Todor Dimitroff


The current study was designed to investigate direct inhibitory effects of N-acetylglucosaminyl-muramyldipeptide (GMDP) over the cytotoxic nature of TNF-α. A lactate dehydrogenase (LDH) assay of the inhibition of TNF-α cytotoxicity was donein vitro on the following cell lines: A549 (human lung carcinoma cells), A431 (human breast cancer cells) and L929 (mouse breast cancer cells). In a double-blind placebo-controlled trial, cancer patients with an elevated activity of all five LDH isoensymes were randomized to receive either a GMDP solution or a placebo; 63 patients were evaluated every third day for the mean daily number of episodes of nausea or vomiting, changes in clinical status, cell blood count and blood chemistry. A 95% inhibition of LDH release was noticed on A549 cells. Other cell lines were less sensitive to GMDP, with an observed 72% dose-dependent reduction in LDH activity.In vivo, LDH activity was decreased by 41% (+/−4%) (mean +/−SD) in all 21 subjects who were given 0.5–1.0 mg of GMDP daily. A lowering of LDH activity by 73.4% (+/−4%) was observed in 23 patients who received GMDP at a dosage of 1.5 mg/kg daily. Correspondingly, a 10% (+/−2%) increase in LDH activity was noticed in 19 patients who were given a placebo (P<0.01). During the follow-up period, the overall clinical condition of all patients treated with GMDP was improved. No side effects were observed. In nine patients who experienced nausea from tumor toxicity before treatment, the symptom subsided. In parallel, an extremely beneficial effect on lipids metabolism was noticed in all patients with elevated cholesterol and trigliceride levels. A dietary supplementation of GMDP has been shown to reduce systemic TNF-α cytotoxicity during tumor shock.


TNF-α LDH N-acetyl-glucosaminyl-muramyldipeptide (GMDP) tumor shock GGTP 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Carswell EA, Old LJ, Kassel RL, Williamson B. An endotoxin induced serum factor that causes necrosis of tumors.Proc Natl Acad Sci 1875;72: 3666–3670.CrossRefGoogle Scholar
  2. 2.
    Goldhaber JIet al. Effect of TNF-alpha on [Ca2+] and contractivity in isolated adult rabbit ventricular myocytes.Am J Physiol 1996;271: H1449-H1455.PubMedGoogle Scholar
  3. 3.
    Heinig Jet al. Semiquantitative determination of IL-1 alpha, TNF-alpha, PDGF-A, PDGF-B, and PDGF-receptor in term human placenta using polymerase chain reaction (PCR).Gynecol 1993;115: 317–322.Google Scholar
  4. 4.
    Recdal O, Osterud B, Svendsen JS, Winberg JO. Evidence for exclusive role of the p55 tumor necrosis factor (TNF) receptor in mediating the TNF-induced collagenase expression by human dermal fibroblasts.J Invest Dermatol 1996;96: 243–249.Google Scholar
  5. 5.
    Owens MW, Grimes SR. Pleural mesothelial cell response to inflammation: tumor necrosis factor induced mitogenesis and collagen synthesis.Am J Physiol 1993;265: L382-L388.PubMedGoogle Scholar
  6. 6.
    Sakayama Ket al. Recombinant human tumour necrosis factor-alpha suppresses synthesis, activity and secretion of lipoprotein lipase in cultures of human osteosarcoma cell line.Biochem J 1996;316: 813–817.PubMedGoogle Scholar
  7. 7.
    Vassalli P. The Pathophysiology of tumor necrosis factors.Annu Rev Immonol 1992;10: 411–452.CrossRefGoogle Scholar
  8. 8.
    Tracey KJ, Beutler B, Lowry SF. Shock and tissue injury induced by recombinant human cachectin.Science 1986;234: 470–474.PubMedCrossRefGoogle Scholar
  9. 9.
    Levine B, Kalman J, Mayer L, Fillit HM. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N Engl J Med 1990;223: 236–241.CrossRefGoogle Scholar
  10. 10.
    Smith SC, Allen PM. Neutrolization of endogenous tumor necrosis factor amiliorates the severity of myosin induced myocarditis.Circ Res 1992;70: 856–863.PubMedGoogle Scholar
  11. 11.
    Imagawa DKet al. The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats.Transplantation 1993;50: 189–193.CrossRefGoogle Scholar
  12. 12.
    Jacobs CA, Smith CA. Methods of lowering active TNF-alpha levels in mammals using tumor necrosis factor receptor. US patent 5605690 1997.Google Scholar
  13. 13.
    Seckinger PL, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor a.J Exp Med 1988;167: 1511–1516.PubMedCrossRefGoogle Scholar
  14. 14.
    Seckinger PL, Zhang JH, Hauptmann B, Dayer JM. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF-receptor.Proc Natl Acad Sci 1990;87: 5188–5192.PubMedCrossRefGoogle Scholar
  15. 15.
    Krueger JM, Pappenhaimer JR, Karnovsky ML. Sleep promoting effects of muramyl peptides.J Biol Chem 1982;257: 1664–1669.PubMedGoogle Scholar
  16. 16.
    Vermeulen MV, David JR, Remold HL. Differential mRNA responses in human macrophages activated by Interferon-y and muramyl peptides.J Immunol 1987;139: 7–9.PubMedGoogle Scholar
  17. 17.
    Slesarev VL, Efimov VA, Oraevsky AV, Slesarev AI. Nonspecific vaccination by D-aminoacid containing compounds: International patent application WO 08/510,737, 1997.Google Scholar
  18. 18.
    Slesarev VI. US patent application 08/757,477, 1996.Google Scholar
  19. 19.
    Ovchinnikov Yuet al. Glycopeptides and methods for preparing same. US patent 4,395,399, 1983.Google Scholar
  20. 20.
    Andronova T, Ivanov V. The structure and immunomodulating function of glucosaminylmuramyl peptides.Sov Med Rev Immunol 1989;4: 1–63.Google Scholar
  21. 21.
    Adeleye TA, Moreno C, Ivanyi J, Aston R. The modulation of tumor necrosis factor-a, interleukin-1a and glucose levels with GMDP and other analogues of muramyl dipeptide.APMS 1994;102: 145–152.CrossRefGoogle Scholar
  22. 22.
    Hornung RL, Longo DL, Gowda VL, Kwak LW. Induction of CD8+ cytotoxic lymphocyte response to a soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(b1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).Ther Immunol 1995;2: 7–14.PubMedGoogle Scholar
  23. 23.
    Barbara JA, Van Ostade X, Lopez A. Tumor necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective.Immunol Cell Biol 1996;74: 434–443.PubMedCrossRefGoogle Scholar
  24. 24.
    Aston R. Muramyl compounds for treatment of septic shock. US patent 5506204, 1996.Google Scholar
  25. 25.
    Preketes APet al. Immunological activity and serum CEA levels following oral administration of muramyl dipeptide (GMDP) to patients with advanced colorectal cancer.Surg Res Comm 1996;18: 137–146.Google Scholar

Copyright information

© Stockton Press All rights reserved 1998

Authors and Affiliations

  • Vladimir I Slesarev
    • 1
  • Rita Ellithorpe
    • 1
  • Todor Dimitroff
    • 1
  1. 1.The Institute of Infectious Gynecology, Inc.ConrocUSA

Personalised recommendations